The Valley Desk

NCT02499770 · Interventional trial

Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC)

Overall registry status Completed

Phase 1 · Phase 2

Conditions Small Cell Lung Cancer

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov